Crescent Biopharma (CBIO) vs Zevra Therapeutics (ZVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Zevra Therapeutics (ZVRA) has outperformed Crescent Biopharma (CBIO) over the past year, gaining 1.9% versus a loss of 0.5%. Over five years, ZVRA leads with a +8.8% price change compared with -92.7% for CBIO. Crescent Biopharma is the larger company by market cap ($543.2 million vs $521.3 million), about 1.0 times the size.
Zevra Therapeutics converts more of its revenue into profit, with a net margin of 78.2% versus -1419.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CBIO | ZVRA |
|---|---|---|
| Share price | $13.00 | $8.76 |
| Market cap | $543.21M | $521.26M |
| 1-day change | +0.70% | -3.42% |
| YTD return | +9.61% | -2.23% |
| 1-year return | -0.46% | +1.86% |
| 5-year return | -92.74% | +8.82% |
| P/E ratio (TTM) | — | 7.18 |
| Forward P/E | — | 9.84 |
| EPS (TTM) | $-7.29 | $1.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $10.84M | $106.47M |
| Revenue growth (YoY) | — | +350.91% |
| Net income (latest FY) | $-153.94M | $83.23M |
| Gross margin | — | 84.52% |
| Operating margin | -1407.52% | -59.12% |
| Net margin | -1419.61% | 78.17% |
| 52-week high | $27.41 | $15.04 |
| 52-week low | $8.72 | $8.01 |
| Distance from 52-week high | -52.57% | -41.74% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +148.69% | +162.56% |
| Average volume | 361.17K | 954.53K |
| Shares outstanding | 38.90M | 59.50M |
| Employees | 80 | 61 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Zevra Therapeutics is more profitable, keeping 78.2 cents of every revenue dollar as net income versus -1419.6 cents for Crescent Biopharma.
About Crescent Biopharma
CBIO stock →Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.
Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees
About Zevra Therapeutics
ZVRA stock →Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 61 employees
CBIO vs ZVRA FAQ
Which is bigger, Crescent Biopharma or Zevra Therapeutics?
Crescent Biopharma (CBIO) is larger, with a market capitalization of $543.21M compared with $521.26M for Zevra Therapeutics (ZVRA).
Which stock has performed better over the past year, CBIO or ZVRA?
ZVRA returned +1.86% over the past 12 months, compared with -0.46% for CBIO (price return, excluding dividends). Past performance does not predict future results.
Are Crescent Biopharma and Zevra Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.